Pricing Log in Create free account
Saturday 17 October 2026 Export APYX’s income statement to Excel — free account

Apyx Medical Corporation

APYX Healthcare Medical Devices

Apyx Medical Corporation’s revenue for fiscal 2025 (year ended December 2025) was $52.8 million, up 9.86% from fiscal 2024. In the quarter to June 2026, revenue grew 22.1%, EPS grew 22.2%, free cash flow fell 137.4% and total debt rose 2.74%, each against the same quarter a year earlier.

2.55 0.01 −0.39%
Market cap
$107.8M
P/E
0.0×
Fwd P/E
−16.0×
Dividend yield
—
F-score
4/9
Altman Z
1.10
Beneish M
−2.63
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Apyx Medical Corporation (APYX) Business Profile

Updated before January 2025

Company Overview

Apyx Medical Corporation (APYX), formerly known as Bovie Medical Corporation, is a leading energy technology company specializing in innovative products for the cosmetic surgery and medical markets. Founded in 1982, the company is headquartered in Clearwater, Florida, USA. Over the years, APYX has transitioned from a general medical device manufacturer to a focused provider of advanced energy-based solutions. The company is led by a team of experienced professionals, with Charlie Goodwin serving as the President and Chief Executive Officer. Under his leadership, APYX has continued to expand its product portfolio and strengthen its position in the global medical technology market.

Core Business Segments

APYX operates primarily in two core business segments: Advanced Energy and OEM (Original Equipment Manufacturer). These segments cater to different aspects of the medical and cosmetic industries, offering a range of products and services.

Advanced Energy

The Advanced Energy segment is the cornerstone of APYX’s business. This segment focuses on the development and commercialization of proprietary helium plasma and radiofrequency (RF) technologies. The flagship product under this category is the Renuvion® system, a groundbreaking device used in cosmetic surgery and medical procedures. Renuvion® combines helium plasma with RF energy to deliver precise tissue contraction and coagulation, making it a preferred choice for skin tightening and other minimally invasive procedures. This technology is widely recognized for its safety, efficacy, and versatility.

OEM (Original Equipment Manufacturer)

In the OEM segment, APYX collaborates with other medical device companies to design and manufacture electrosurgical equipment and accessories. This includes generators, electrodes, and other components that are integral to surgical procedures. By leveraging its expertise in energy-based technologies, APYX provides high-quality, reliable products to its OEM partners, contributing to the broader medical device ecosystem.

Business Model

APYX’s business model revolves around innovation, quality, and customer-centricity. The company generates revenue through the sale of its proprietary products, licensing agreements, and OEM partnerships. By integrating advanced technologies into its product offerings, APYX ensures that its solutions meet the evolving needs of healthcare professionals and patients. The company also invests heavily in research and development (R&D) to maintain its competitive edge and drive long-term growth.

APYX’s approach to customer engagement includes comprehensive training programs, technical support, and marketing assistance for its clients. This holistic strategy not only enhances customer satisfaction but also fosters brand loyalty and repeat business.

Strategic Direction

APYX is committed to expanding its presence in the global medical and cosmetic markets. The company’s strategic priorities include:

  • Product Innovation: Continuously developing new technologies and enhancing existing products to address unmet clinical needs.
  • Market Expansion: Increasing its footprint in international markets through strategic partnerships and regulatory approvals.
  • Sustainability Goals: Implementing environmentally friendly practices in its operations and product development processes.
  • Diversification: Exploring new product categories and applications for its core technologies to reduce dependence on specific markets.

By focusing on these areas, APYX aims to achieve sustainable growth and solidify its position as a leader in energy-based medical technologies.

Competitive Landscape

APYX operates in a highly competitive industry, facing competition from both established players and emerging companies. Key competitors include:

  • Cutera, Inc.: A provider of laser and energy-based aesthetic systems.
  • Cynosure: Known for its wide range of aesthetic treatment devices.
  • Hologic, Inc.: A major player in medical and aesthetic technologies.
  • Medtronic: A global leader in medical devices and therapies.

Despite the competitive landscape, APYX differentiates itself through its proprietary technologies, strong customer relationships, and focus on innovation.

Risk Factors

Like any business, APYX faces several risks that could impact its operations and financial performance. Key risk factors include:

  • Market Dependence: A significant portion of the company’s revenue comes from the Renuvion® system, making it vulnerable to market fluctuations and competitive pressures.
  • Regulatory Challenges: Compliance with stringent regulatory requirements in different countries can be time-consuming and costly.
  • Supply Chain Disruptions: Dependence on third-party suppliers for raw materials and components exposes the company to potential supply chain disruptions.
  • Economic Conditions: Economic downturns and reduced healthcare spending could negatively affect demand for APYX’s products.

Recent Developments

APYX has made significant strides in recent years, including:

  • Product Launches: The introduction of new Renuvion® handpieces and accessories to enhance the versatility of the system.
  • Regulatory Approvals: Securing FDA clearances for additional indications, expanding the potential applications of its technologies.
  • Strategic Partnerships: Collaborating with leading medical institutions and organizations to drive adoption of its products.
  • Global Expansion: Establishing a stronger presence in key international markets, including Europe and Asia.

These developments underscore APYX’s commitment to innovation and growth.

Investment Considerations

Investors considering APYX should weigh the following factors:

Strengths

  • Innovative Technology: Proprietary helium plasma and RF technologies set APYX apart from competitors.
  • Growing Market: Increasing demand for minimally invasive cosmetic procedures provides a favorable market environment.
  • Strong Leadership: Experienced management team with a proven track record of success.

Risks

  • Market Concentration: Heavy reliance on a single product line could pose challenges.
  • Regulatory Risks: Potential delays or denials in regulatory approvals could impact growth.
  • Economic Sensitivity: Demand for elective procedures may decline during economic downturns.

Conclusion

APYX Medical Corporation is a dynamic player in the medical technology industry, known for its innovative energy-based solutions. With a strong focus on R&D, strategic partnerships, and market expansion, the company is well-positioned for future growth. However, investors should carefully consider the associated risks before making investment decisions. Overall, APYX’s commitment to innovation and quality makes it a compelling choice for healthcare professionals and investors alike.